Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in COVID-19 Cytokine Storm Syndrome
NCT04443881Phase 3Completed
- Sponsor
- Fundación Miguel Servet
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anakinra in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) (2 arms), sponsored by Fundación Miguel Servet. Primary endpoint: Treatment success defined as number of patients not requiring mechanical ventilation at Day 15. Started May 2020; status: completed.
02
Drugs
anakinra
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04443881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443881.